BFC Planning’s Silexion Therapeutics SLXN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$37 Hold
6
– – ﹤0.01% 3426
2026
Q2
$339 Buy
+6
New +$869 ﹤0.01% 3287

Other funds holding SLXN

BFC Planning's SLXN Position: Q3 2026 in Review

BFC Planning held its Silexion Therapeutics (SLXN) position steady in Q3 2026 at 6 shares worth $37. The position accounts for ﹤0.01% of the portfolio, ranked #3426.

BFC Planning first reported a position in SLXN in Q2 2026 and has held it in 2 quarters since. The position peaked at $339 in Q2 2026. 7 funds tracked by Wall St. Rank hold SLXN as of Q3 2026.

  • BFC Planning held 6 shares of Silexion Therapeutics worth $37 as of Q3 2026.
  • BFC Planning left its Silexion Therapeutics share count unchanged in Q3 2026.
  • Silexion Therapeutics made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #3426 holding.
  • BFC Planning first reported a position in Silexion Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • BFC Planning's Silexion Therapeutics position peaked at $339 in Q2 2026.
  • 7 funds tracked by Wall St. Rank held Silexion Therapeutics as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.